Article

Lunai Bioworks Inc. has identified three revenue-generating segments: AI drug discovery, AI bio-defense, and immunotherapy. The Sacramento company completed its AI platform in the past year and is negotiating partnerships with pharmaceutical companies.

In the AI drug discovery segment, Lunai collaborates with Supernus Pharmaceuticals for an epilepsy trial and has a new oncology partnership for colorectal cancer. The bio-defense segment includes Sentinel, Pathfinder, and CounterAct, with negotiations ongoing with governmental and private partners. For immunotherapy, Lunai's dendritic cell therapy showed complete regression of pancreatic tumors in preclinical models, with a letter of intent for licensing received.